New Technologies for the Highly Parallel Optimization of Cell Culture Processes

The EU Commission and the “European Federation of Pharmaceutical Industries and Associations” (EFPIA) have announced funding for another joint research project called iConsensus. The project has the aim of developing new scientific methods for the optimization of cell cultures. Cell cultures are used especially in the development and production of complex pharmaceuticals. In this way, highly effective substances can be produced in a biological manner. Environmental pollution which could be linked to chemical production processes is, for the most part, avoided completely.

Within this project, m2p-labs GmbH will be developing a new device in cooperation with other specialized companies and prestigious research facilities in Europe to be able to improve cell culture processes quickly and transfer them to the production scale. m2p-labs will benefit from the expertise of involved pharmaceutical companies in terms of product requirements and future research applications of the new device generation. A central element of the cooperation with the involved research facilities will be the online 2D fluorescence spectroscopy1), used for the analysis of parallel miniaturized cell cultures for the first time.

“The iConsensus project represents an ideal expansion of our internal activities in the further development of our BioLector technology”, Anna Kress says, Head of the Mammalian Cell Cultures area at m2p-labs. “The combination of our online biomass, pH and oxygen measurement in microtiter plates with 2-dimensional spectroscopic methods has the potential to start a new chapter in the automated process development of cell cultures.”

For more cell culture news and products, visit our Life Sciences community